Back

Extremely Long Duration Lp(a) Reduction Following a Single Dose of Kylo-11: Final Data from a First-in-Human Study

28 August 2026 (17:00 - 17:15)
Organised by: Logo
Congress Presentation Part of: Late-Breaking Clinical Trials: rewriting cardiovascular disease on gene and molecular therapies Drug therapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Ashish Sarraju

Cleveland Clinic, Cleveland (United States of America)

3 More presentations in this session

Presentation thumbnail
Angiopoietin-like 3 antibody rivocibart for homozygous familial hypercholesterolemia
Professor D. Peng (Changsha, CN)
Slides Video
Presentation thumbnail
Durability of Effects of CTX310, a CRISPR-Cas9 Gene Editing Targeting ANGPTL3
Associate Professor L. Laffin (Cleveland, US)
Video
Presentation thumbnail
AAV8-mediated gene therapy for homozygous familial hypercholesterolemia
Doctor T. Li (Xi'an, CN)
Video

Access the full session

Session thumbnail
Late-Breaking Clinical Trials: rewriting cardiovascular disease on gene and molecular therapies
Video

The Event

Event poster

ESC Congress 2026

28 August 2026 17:00 CET
You may be interested in
thumbnail
Congress Presentation
siRNAs to lower Lp(a)
28 August 2026
thumbnail
Congress Presentation
SHR-1918, a monoclonal antibody against angiopoietin-like 3, in healthy subjects: a randomized, double-blind, placebo-controlled, phase 1 study
1 September 2024
thumbnail
Congress Presentation
Pelacarsen reduces the need for lipoprotein apheresis in patients with elevated lipoprotein(a) and cardiovascular disease: The Phase 3 Lp(a)FRONTIERS APHERESIS trial
29 August 2025
thumbnail
Congress Presentation
FOURIER-OLE: Primary Results.
29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources